Prostaglandin E3 metabolism and cancer

Cancer Letters

Volumn 348, Issue 1-2, 2014, Pages 1-11

  Yang, Peiying ^a   Jiang, Yan ^a   Fischer, Susan M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer cells; Metabolism; N 3 Fatty acids; Tumor tissues

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOSOLIC PHOSPHOLIPASE A2; DOCOSAHEXAENOIC ACID; DRUG METABOLITE; FATTY ACID; FISH OIL; ICOSANOID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPID; PROSTAGLANDIN E3; PROSTAGLANDIN RECEPTOR; TUMOR MARKER; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PHOSPHOLIPASE A2 GROUP IV; PROSTAGLANDIN E1; PROSTAGLANDIN E2;

ANTINEOPLASTIC ACTIVITY; BIOSYNTHESIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FAT INTAKE; FATTY ACID METABOLISM; FATTY ACID SYNTHESIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NONHUMAN; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN METABOLISM; PROSTAGLANDIN SYNTHESIS INHIBITION; PROSTAGLANDIN URINE LEVEL; PROSTATE CANCER; PROTEIN LIPID INTERACTION; SHORT SURVEY; TISSUE LEVEL; TREATMENT RESPONSE; ANIMAL; CANCER CELLS; DRUG EFFECT; METABOLISM; N-3 FATTY ACIDS; NEOPLASM; PATHOLOGY; PGE(3); REVIEW; SIGNAL TRANSDUCTION; TUMOR TISSUES;

CANCER CELLS; METABOLISM; N-3 FATTY ACIDS; PGE(3); TUMOR TISSUES;

ALPROSTADIL; ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE 2; DINOPROSTONE; EICOSAPENTAENOIC ACID; GROUP IV PHOSPHOLIPASES A2; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84900497242     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.03.010     Document Type: Review

References (121)

1. Rothwell P.M., Wilson M., Elwin C.E., Norrving B., Algra A., Warlow C.P., Meade T.W. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010, 376:1741-1750.
2. Chan A.T., Ogino S., Fuchs C.S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. New Engl. J. Med. 2007, 356:2131-2142.
3. Chan A.T., Ogino S., Fuchs C.S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009, 302:649-658.
4. McCarty M.F. Minimizing the cancer-promotional activity of cox-2 as a central strategy in cancer prevention. Med. Hypotheses 2012, 78:45-57.
5. Wang D., Dubois R.N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010, 29:781-788.
6. Xia D., Wang D., Kim S.H., Katoh H., DuBois R.N. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat. Med. 2012, 18:224-226.
7. Park Y., Harris W.S. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J. Lipid Res. 2003, 44:455-463.
8. Qi K., Fan C., Jiang J., Zhu H., Jiao H., Meng Q., Deckelbaum R.J. Omega-3 fatty acid containing diets decrease plasma triglyceride concentrations in mice by reducing endogenous triglyceride synthesis and enhancing the blood clearance of triglyceride-rich particles. Clin. Nutr. 2008, 27:424-430.
9. Smith W. Cyclooxygenases, peroxide tone and the allure of fish oil. Curr. Opin. Cell Biol. 2005, 17:174-182.
10. Spencer L., Mann C., Metcalfe M., Webb M., Pollard C., Spencer D., Berry D., Steward W., Dennison A. The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. Eur. J. Cancer 2009, 45:2077-2086.
11. Riediger N.D., Othman R.A., Suh M., Moghadasian M.H. A systemic review of the roles of n-3 fatty acids in health and disease. J. Am. Diet. Assoc. 2009, 109:668-679.
12. Jing K., Wu T., Lim K. Omega-3 polyunsaturated fatty acids and cancer. Anticancer Agents Med. Chem. 2013, 13:1162-1177.
13. Cockbain A.J., Toogood G.J., Hull M.A. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut 2011, 61:135-149.
14. Fradet V., Cheng I., Casey G., Witte J.S. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin. Cancer Res. 2009, 15:2559-2566.
15. Patterson R.E., Flatt S.W., Newman V.A., Natarajan L., Rock C.L., Thomson C.A., Caan B.J., Parker B.A., Pierce J.P. Marine fatty acid intake is associated with breast cancer prognosis. J. Nutr. 2011, 141:201-206.
16. Takezaki T., Hirose K., Inoue M., Hamajima N., Yatabe Y., Mitsudomi T., Sugiura T., Kuroishi T., Tajima K. Dietary factors and lung cancer risk in Japanese: with special reference to fish consumption and adenocarcinomas. Br. J. Cancer 2001, 84:1199-1206.
17. Rhodes L.E., Shahbakhti H., Azurdia R.M., Moison R.M., Steenwinkel M.J., Homburg M.I., Dean M.P., McArdle F., Beijersbergen van Henegouwen G.M., Epe B., Vink A.A. Effect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markers. Carcinogenesis 2003, 24:919-925.
18. Serhan C.N. Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr. Opin. Clin. Nutr. Metab. Care 2005, 8:115-121.
19. Janakiram N.B., Mohammed A., Rao C.V. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metast. Rev. 2011, 30:507-523.
20. Greene E.R., Huang S., Serhan C.N., Panigrahy D. Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat. 2011, 96:27-36.
21. Yang P., Chan D., Felix E., Cartwright C., Menter D.G., Madden T., Klein R.D., Fischer S.M., Newman R.A. Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J. Lipid Res. 2004, 45:1030-1039.
22. Wada M., DeLong C.J., Hong Y.H., Rieke C.J., Song I., Sidhu R.S., Yuan C., Warnock M., Schmaier A.H., Yokoyama C., Smyth E.M., Wilson S.J., FitzGerald G.A., Garavito R.M., Sui de X., Regan J.W., Smith W.L. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J. Biol. Chem. 2007, 282:22254-22266.
23. Hegde S., Kaushal N., Ravindra K.C., Chiaro C., Hafer K.T., Gandhi U.H., Thompson J.T., van den Heuvel J.P., Kennett M.J., Hankey P., Paulson R.F., Prabhu K.S. Delta12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice. Blood 2011, 118:6909-6919.
24. Hawcroft G., Loadman P.M., Belluzzi A., Hull M.A. Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells. Neoplasia 2010, 12:618-627.
25. Fan Y.Y., Davidson L.A., Callaway E.S., Goldsby J.S., Chapkin R.S. Differential effects of 2 and 3-series E-prostaglandins on in vitro expansion of Lgr5+ intestinal stem cells. Carcinogenesis 2014, Epub ahead of print.
26. Marszalek J.R., Lodish H.F. Docosahexaenoic acid, fatty acid-interacting proteins, and neuronal function: breastmilk and fish are good for you. Annu. Rev. Cell Dev. Biol. 2005, 21:633-657.
27. Goyens P.L., Spilker M.E., Zock P.L., Katan M.B., Mensink R.P. Compartmental modeling to quantify alpha-linolenic acid conversion after longer term intake of multiple tracer boluses. J. Lipid Res. 2005, 46:1474-1483.
28. Kaur G., Cameron-Smith D., Garg M., Sinclair A.J. Docosapentaenoic acid (22:5n-3): a review of its biological effects. Prog. Lipid Res. 2011, 50:28-34.
29. Burdge G.C., Wootton S.A. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br. J. Nutr. 2002, 88:411-420.
30. Burdge G.C., Finnegan Y.E., Minihane A.M., Williams C.M., Wootton S.A. Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [13C] alpha-linolenic acid to longer-chain fatty acids and partitioning towards beta-oxidation in older men. Br. J. Nutr. 2003, 90:311-321.
31. *. Br. J. Nutr. 2002, 88:355-363.
32. Arterburn L.M., Hall E.B., Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am. J. Clin. Nutr. 2006, 83:1467S-1476S.
33. Stark K.D., Holub B.J. Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am. J. Clin. Nutr. 2004, 79:765-773.
34. Conquer J.A., Holub B.J. Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. J. Nutr. 1996, 126:3032-3039.
35. Conquer J.A., Holub B.J. Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians and omnivores. Lipids 1997, 32:341-345.
36. Mozaffarian D., Wu J.H. (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary?. J. Nutr. 2012, 142:614S-625S.
37. Vermunt S.H., Mensink R.P., Simonis M.M., Hornstra G. Effects of dietary alpha-linolenic acid on the conversion and oxidation of 13C-alpha-linolenic acid. Lipids 2000, 35:137-142.
38. Emken E.A., Adlof R.O., Gulley R.M. Dietary linoleic acid influences desaturation and acylation of deuterium-labeled linoleic and linolenic acids in young adult males. Biochim. Biophys. Acta 1994, 1213:277-288.
39. Ervin R.B., Wright J.D., Wang C.Y., Kennedy-Stephenson J. Dietary intake of fats and fatty acids for the United States population: 1999-2000. Adv. Data 2004, 1-6.
40. Miller E., Kaur G., Larsen A., Loh S.P., Linderborg K., Weisinger H.S., Turchini G.M., Cameron-Smith D., Sinclair A.J. A short-term n-3 DPA supplementation study in humans. Eur. J. Nutr. 2013, 52:895-904.
41. Ghasemi Fard S., Linderborg K.M., Turchini G.M., Sinclair A.J. Comparison of the bioavailability of docosapentaenoic acid (DPA, 22:5n-3) and eicosapentaenoic acid (EPA, 20:5n-3) in the rat. Prostaglandins Leukot Essent Fatty Acids 2014, 90:23-26.
42. Linderborg K.M., Kaur G., Miller E., Meikle P.J., Larsen A.E., Weir J.M., Nuora A., Barlow C.K., Kallio H.P., Cameron-Smith D., Sinclair A.J. Postprandial metabolism of docosapentaenoic acid (DPA, 22:5n-3) and eicosapentaenoic acid (EPA, 20:5n-3) in humans. Prostaglandins Leukot Essent Fatty Acids 2013, 88:313-319.
43. Fischer S., von Schacky C., Siess W., Strasser T., Weber P.C. Uptake, release and metabolism of docosahexaenoic acid (DHA, c22:6 omega 3) in human platelets and neutrophils. Biochem. Biophys. Res. Commun. 1984, 120:907-918.
44. Samuelsson B. Prostaglandins, thromboxanes, and leukotrienes: formation and biological roles. Harvey Lect. 1979, 75:1-40.
45. Bagga D., Wang L., Farias-Eisner R., Glaspy J.A., Reddy S.T. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc. Natl. Acad. Sci. USA 2003, 100:1751-1756.
46. Lorenz R., Spengler U., Fischer S., Duhm J., Weber P.C. Platelet function, thromboxane formation and blood pressure control during supplementation of the Western diet with cod liver oil. Circulation 1983, 67:504-511.
47. Phang M., Lincz L.F., Garg M.L. Eicosapentaenoic and docosahexaenoic acid supplementations reduce platelet aggregation and hemostatic markers differentially in men and women. J. Nutr. 2013, 143:457-463.
48. Dehmer G.J., Popma J.J., van den Berg E.K., Eichhorn E.J., Prewitt J.B., Campbell W.B., Jennings L., Willerson J.T., Schmitz J.M. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. New Engl. J. Med. 1988, 319:733-740.
49. Dessi M., Noce A., Bertucci P., Manca di Villahermosa S., Zenobi R., Castagnola V., Addessi E., Di Daniele N. Atherosclerosis, Dyslipidemia, and Inflammation: The Significant Role of Polyunsaturated Fatty Acids. ISRN Inflammat. 2013, 2013:191823.
50. Funahashi H., Satake M., Hasan S., Sawai H., Newman R.A., Reber H.A., Hines O.J., Eibl G. Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Pancreas 2008, 36:353-362.
51. Vanamala J., Glagolenko A., Yang P., Carroll R.J., Murphy M.E., Newman R.A., Ford J.R., Braby L.A., Chapkin R.S., Turner N.D., Lupton J.R. Dietary fish oil and pectin enhance colonocyte apoptosis in part through suppression of PPARdelta/PGE2 and elevation of PGE3. Carcinogenesis 2008, 29:790-796.
52. Rubin D., Laposata M. Cellular interactions between n-6 and n-3 fatty acids: a mass analysis of fatty acid elongation/desaturation, distribution among complex lipids, and conversion to eicosanoids. J. Lipid Res. 1992, 33:1431-1440.
53. Smith W., Murphy R. The eicosanoids: cyclooxygenase, lipoxygenase, and epoxygenase pathways. Biochemistry of Lipids 2002, 341-372. Lipoproteins and Membranes, Elsevier, Amsterdam. D. Vance, J. Vance (Eds.).
54. Smith W.L. Nutritionally essential fatty acids and biologically indispensable cyclooxygenases. Trends Biochem. Sci. 2008, 33:27-37.
55. Mahadevappa V.G., Holub B.J. Quantitative loss of individual eicosapentaenoyl-relative to arachidonoyl-containing phospholipids in thrombin-stimulated human-platelets. J. Lipid Res. 1987, 28:1275-1280.
56. Clark J.D., Schievella A.R., Nalefski E.A., Lin L.L. Cytosolic Phospholipase a(2). J. Lipid Mediat. Cell 1995, 12:83-117.
57. Leslie C.C. Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2. Prostaglandins Leukot Essent Fatty Acids 2004, 70:373-376.
58. Laneuville O., Breuer D.K., Xu N., Huang Z.H., Gage D.A., Watson J.T., Lagarde M., DeWitt D.L., Smith W.L. Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)- octadecatrienoic acids from alpha-linolenic acid. J. Biol. Chem. 1995, 270:19330-19336.
59. Liu W., Cao D., Oh S.F., Serhan C.N., Kulmacz R.J. Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. Faseb J. 2006, 20:1097-1108.
60. Tanikawa N., Ohmiya Y., Ohkubo H., Hashimoto K., Kangawa K., Kojima M., Ito S., Watanabe K. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem. Biophys. Res. Commun. 2002, 291:884-889.
61. Wada M., Yokoyama C., Hatae T., Shimonishi M., Nakamura M., Imai Y., Ullrich V., Tanabe T. Purification and characterization of recombinant human prostacyclin synthase. J. Biochem. 2004, 135:455-463.
62. Hecker M., Ullrich V. On the mechanism of prostacyclin and thromboxane-A2 biosynthesis. J. Biol. Chem. 1989, 264:141-150.
63. Kung-Chao D.T., Tai H.H. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase from porcine kidney. I. Purification and partial characterization. Biochim. Biophys. Acta 1980, 614:1-13.
64. Belury M.A., Patrick K.E., Locniskar M., Fischer S.M. Eicosapentaenoic and arachidonic acid: comparison of metabolism and activity in murine epidermal cells. Lipids 1989, 24:423-429.
65. Norris P.C., Dennis E.A. Omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling. Proc. Natl. Acad. Sci. USA 2012, 109:8517-8522.
66. Obata T., Nagakura T., Masaki T., Maekawa K., Yamashita K. Eicosapentaenoic acid inhibits prostaglandin D-2 generation by inhibiting cyclo-oxygenase-2 in cultured human mast cells. Clin. Exp. Allergy 1999, 29:1129-1135.
67. Neilson A.P., Djuric Z., Ren J.W., Hong Y.H., Sen A., Lager C., Jiang Y., Reuven S., Smith W.L., Brenner D.E. Effect of cyclooxygenase genotype and dietary fish oil on colonic eicosanoids in mice. J. Nutr. Biochem. 2012, 23:966-976.
68. Pirman D.A., Efuet E., Ding X.P., Pan Y., Tan L., Fischer S.M., DuBois R.N., Yang P. Changes in cancer cell metabolism revealed by direct sample analysis with MALDI mass spectrometry. PLoS ONE 2013, 8:e61379.
69. Kearns R.J., Hayek M.G., Turek J.J., Meydani M., Burr J.R., Greene R.J., Marshall C.A., Adams S.M., Borgert R.C., Reinhart G.A. Effect of age, breed and dietary omega-6 (n-6): omega-3 (n-3) fatty acid ratio on immune function, eicosanoid production, and lipid peroxidation in young and aged dogs. Vet. Immunol. Immunopathol. 1999, 69:165-183.
70. Kiriyama M., Ushikubi F., Kobayashi T., Hirata M., Sugimoto Y., Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Clin. Pharmacol. 1997, 122:217-224.
71. Coleman R.A., Smith W.L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 1994, 46:205-229.
72. Iyu D., Glenn J.R., White A.E., Johnson A., Heptinstall S., Fox S.C. The role of prostanoid receptors in mediating the effects of PGE3 on human platelet function. Thromb. Haemost. 2012, 107:797-799.
73. Bansal V., Syres K.M., Makarenkova V., Brannon R., Matta B., Harbrecht B.G., Ochoa J.B. Interactions between fatty acids and arginine metabolism: implications for the design of immune-enhancing diets. J. Parenter. Enteral. Nutr. 2005, 29:S75.
74. Greenhough A., Smartt H.J., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
75. Hawcroft G., Volpato M., Marston G., Ingram N., Perry S.L., Cockbain A.J., Race A.D., Munarini A., Belluzzi A., Loadman P.M., Coletta P.L., Hull M.A. The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of PGE2-dependent cell motility. Br. J. Pharmacol. 2012, 166:1724-1737.
76. Calviello G., Di Nicuolo F., Gragnoli S., Piccioni E., Serini S., Maggiano N., Tringali G., Navarra P., Ranelletti F.O., Palozza P. N-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway. Carcinogenesis 2004, 25:2303-2310.
77. Bonventre J.V., Huang Z., Taheri M.R., O'Leary E., Li E., Moskowitz M.A., Sapirstein A. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 1997, 390:622-625.
78. Uozumi N., Kume K., Nagase T., Nakatani N., Ishii S., Tashiro F., Komagata Y., Maki K., Ikuta K., Ouchi Y., Miyazaki J., Shimizu T. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 1997, 390:618-622.
79. Xia S.H., Wang J.D., He C.W., Hong S., Serhan C.N., Kang J.X. Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc. Natl. Acad. Sci. USA 2006, 103:12499-12504.
80. Yang P., Cartwright C., Chan D., Ding J., Felix E., Pan Y., Pang J., Rhea P., Block K., Fischer S.M., Newman R.A. Anticancer activity of fish oils against human lung cancer is associated with changes in formation of PGE(2) and PGE(3) and Alteration of Akt Phosphorylation. Mol. Carcinogen. 2013, Epub ahead of print.
81. Tashjian A.H., Voelkel E.F., Robinson D.R., Levine L. Dietary menhaden oil lowers plasma prostaglandins and calcium in mice bearing the prostaglandin-producing HSDM1 fibrosarcoma. J. Clin. Invest. 1984, 74:2042-2048.
82. Takahashi M., Fukutake M., Isoi T., Fukuda K., Sato H., Yazawa K., Sugimura T., Wakabayashi K. Suppression of azoxymethane-induced rat colon carcinoma development by a fish oil component, docosahexaenoic acid (DHA). Carcinogenesis 1997, 18:1337-1342.
83. Bartram H.P., Gostner A., Scheppach W., Reddy B.S., Rao C.V., Dusel G., Richter F., Richter A., Kasper H. Effects of fish oil on rectal cell proliferation, mucosal fatty acids, and prostaglandin E2 release in healthy subjects. Gastroenterology 1993, 105:1317-1322.
84. Minoura T., Takata T., Sakaguchi M., Takada H., Yamamura M., Hioki K., Yamamoto M. Effect of dietary eicosapentaenoic acid on azoxymethane-induced colon carcinogenesis in rats. Cancer Res. 1988, 48:4790-4794.
85. Karmali R.A., Reichel P., Cohen L.A., Terano T., Hirai A., Tamura Y., Yoshida S. The effects of dietary omega-3 fatty acids on the DU-145 transplantable human prostatic tumor. Anticancer Res. 1987, 7:1173-1179.
86. Sasaki T., Kobayashi Y., Shimizu J., Wada M., In'nami S., Kanke Y., Takita T. Effects of dietary n-3-to-n-6 polyunsaturated fatty acid ratio on mammary carcinogenesis in rats. Nutr. Cancer 1998, 30:137-143.
87. de Bravo M.G., de Antueno R.J., Toledo J., De Tomas M.E., Mercuri O.F., Quintans C. Effects of an eicosapentaenoic and docosahexaenoic acid concentrate on a human lung carcinoma grown in nude mice. Lipids 1991, 26:866-870.
88. Yang P., Chan D., Felix E., Madden T., Klein R.D., Shureiqi I., Chen X., Dannenberg A.J., Newman R.A. Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids. Prostaglandins Leukot Essent Fatty Acids 2006, 75:385-395.
89. Yang P., Felix E., Madden T., Fischer S.M., Newman R.A. Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells. Anal. Biochem. 2002, 308:168-177.
90. Zou Z., Bellenger S., Massey K.A., Nicolaou A., Geissler A., Bidu C., Bonnotte B., Pierre A.S., Minville-Walz M., Rialland M., Seubert J., Kang J.X., Lagrost L., Narce M., Bellenger J. Inhibition of the HER2 pathway by n-3 polyunsaturated fatty acids prevents breast cancer in fat-1 transgenic mice. J. Lipid Res. 2013, 54:3453-3463.
91. Zeng L., An S., Goetzl E.J. EP4/EP2 receptor-specific prostaglandin E2 regulation of interleukin-6 generation by human HSB.2 early T cells. J. Pharmacol. Exp. Ther. 1998, 286:1420-1426.
92. Hagi A., Nakayama M., Miura Y., Yagasaki K. Effects of a fish oil-based emulsion on rat hepatoma cell invasion in culture. Nutrition 2007, 23:871-877.
93. Szymczak M., Murray M., Petrovic N. Modulation of angiogenesis by omega-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood 2008, 111:3514-3521.
94. Denkins Y., Kempf D., Ferniz M., Nileshwar S., Marchetti D. Role of omega-3 polyunsaturated fatty acids on cyclooxygenase-2 metabolism in brain-metastatic melanoma. J. Lipid Res. 2005, 46:1278-1284.
95. Bartoli G.M., Palozza P., Marra G., Armelao F., Franceschelli P., Luberto C., Sgarlata E., Piccioni E., Anti M. N-3 PUFA and alpha-tocopherol control of tumor cell proliferation. Mol. Aspects Med. 1993, 14:247-252.
96. Gallai V., Sarchielli P., Trequattrini A., Franceschini M., Floridi A., Firenze C., Alberti A., Di Benedetto D., Stragliotto E. Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J. Neuroimmunol. 1995, 56:143-153.
97. Swails W.S., Kenler A.S., Driscoll D.F., DeMichele S.J., Babineau T.J., Utsunamiya T., Chavali S., Forse R.A., Bistrian B.R. Effect of a fish oil structured lipid-based diet on prostaglandin release from mononuclear cells in cancer patients after surgery. JPEN J. Parenter Enteral. Nutr. 1997, 21:266-274.
98. Faber J., Berkhout M., Fiedler U., Avlar M., Witteman B.J., Vos A.P., Henke M., Garssen J., van Helvoort A., Otten M.H., Arends J. Rapid EPA and DHA incorporation and reduced PGE2 levels after one week intervention with a medical food in cancer patients receiving radiotherapy, a randomized trial. Clin. Nutr. 2013, 32:338-345.
99. Warstedt K., Furuhjelm C., Duchen K., Falth-Magnusson K., Fageras M. The effects of omega-3 fatty acid supplementation in pregnancy on maternal eicosanoid, cytokine, and chemokine secretion. Pediatr Res. 2009, 66:212-217.
100. Trebble T.M., Wootton S.A., Miles E.A., Mullee M., Arden N.K., Ballinger A.B., Stroud M.A., Burdge G.C., Calder P.C. Prostaglandin E2 production and T cell function after fish-oil supplementation: response to antioxidant cosupplementation. Am. J. Clin. Nutr. 2003, 78:376-382.
101. Dawczynski C., Massey K.A., Ness C., Kiehntopf M., Stepanow S., Platzer M., Grun M., Nicolaou A., Jahreis G. Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors. Clin. Nutr. 2013, 32:686-696.
102. Rees D., Miles E.A., Banerjee T., Wells S.J., Roynette C.E., Wahle K.W., Calder P.C. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am. J. Clin. Nutr. 2006, 83:331-342.
103. La Guardia M., Giammanco S., Di Majo D., Tabacchi G., Tripoli E., Giammanco M. Omega 3 fatty acids: biological activity and effects on human health. Panminerva Med. 2005, 47:245-257.
104. Kobayashi N., Barnard R.J., Henning S.M., Elashoff D., Reddy S.T., Cohen P., Leung P., Hong-Gonzalez J., Freedland S.J., Said J., Gui D., Seeram N.P., Popoviciu L.M., Bagga D., Heber D., Glaspy J.A., Aronson W.J. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin. Cancer Res. 2006, 12:4662-4670.
105. Petrik M.B., McEntee M.F., Chiu C.H., Whelan J. Antagonism of arachidonic acid is linked to the antitumorigenic effect of dietary eicosapentaenoic acid in Apc(Min/+) mice. J. Nutr. 2000, 130:1153-1158.
106. Bose M., Hao X., Ju J., Husain A., Park S., Lambert J.D., Yang C.S. Inhibition of tumorigenesis in ApcMin/+ mice by a combination of (-)-epigallocatechin-3-gallate and fish oil. J. Agric. Food Chem. 2007, 55:7695-7700.
107. Hillier K., Jewell R., Dorrell L., Smith C.L. Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 1991, 32:1151-1155.
108. Murphey L.J., Williams M.K., Sanchez S.C., Byrne L.M., Csiki I., Oates J.A., Johnson D.H., Morrow J.D. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal. Biochem. 2004, 334:266-275.
109. Ward P.S., Fuller R.W., Ritter J.M., Cashman S.J., Rees A.J., Dollery C.T. Excretion of metabolites of prostacyclin and thromboxane by rats with nephrotoxic nephritis: effects of interleukin-1. Br. J. Pharmacol. 1991, 103:1663-1668.
110. Kivits G.A., Nugteren D.H. The urinary excretion of prostaglandins E and their corresponding tetranor metabolites by rats fed a diet rich in eicosapentaenoate. Biochim. Biophys. Acta 1988, 958:289-299.
111. Ferretti A., Judd J.T., Taylor P.R., Schatzkin A., Brown C. Modulating influence of dietary lipid intake on the prostaglandin system in adult men. Lipids 1989, 24:419-422.
112. Ferretti A., Judd J.T., Ballard-Barbash R., Nair P.P., Taylor P.R., Clevidence B.A. Effect of fish oil supplementation on the excretion of the major metabolite of prostaglandin E in healthy male subjects. Lipids 1991, 26:500-503.
113. Murff H.J., Shrubsole M.J., Cai Q., Smalley W.E., Dai Q., Milne G.L., Ness R.M., Zheng W. Dietary intake of PUFAs and colorectal polyp risk. Am. J. Clin. Nutr. 2012, 95:703-712.
114. Young L.R., Kurzer M.S., Thomas W., Redmon J.B., Raatz S.K. Effect of dietary fat and omega-3 fatty acids on urinary eicosanoids and sex hormone concentrations in postmenopausal women: a randomized controlled feeding trial. Nutr. Cancer 2011, 63:930-939.
115. Fischer S., von Schacky C., Schweer H. Prostaglandins E3 and F3 alpha are excreted in human urine after ingestion of n-3 polyunsaturated fatty acids. Biochim. Biophys. Acta 1988, 963:501-508.
116. Diczfalusy U., Hamberg M. Identification of the major urinary metabolite of prostaglandin E3 in the rat. Biochim. Biophys. Acta 1986, 878:387-393.
117. Kuklev D.V., Hankin J.A., Uhlson C.L., Hong Y.H., Murphy R.C., Smith W.L. Major urinary metabolites of 6-keto-prostaglandin F2alpha in Mice. J. Lipid Res. 2013, 54:1906-1914.
118. Yin H., Liu W., Goleniewska K., Porter N.A., Morrow J.D., Peebles R.S. Dietary supplementation of omega-3 fatty acid-containing fish oil suppresses F2-isoprostanes but enhances inflammatory cytokine response in a mouse model of ovalbumin-induced allergic lung inflammation. Free Radic. Biol. Med. 2009, 47:622-628.
119. Monneret G., Cossette C., Gravel S., Rokach J., Powell W.S. 15R-methyl-prostaglandin D-2 is a potent and selective CRTH2/DP2 receptor agonist in human eosinophils. J. Pharmacol. Exp. Ther. 2003, 304:349-355.
120. Kobzar G., Mardla V., Jarving I., Samel N. Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets. Cell Physiol. Biochem. 2001, 11:279-284.
121. Regan J.W. EP2 and EP4 prostanoid receptor signaling. Life Sci. 2003, 74:143-153.